Trials / Completed
CompletedNCT05889442
Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab
Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab: A Randomized Double-Blind Placebo-Controlled Two-Way Crossover Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Danish Headache Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. Here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levcromakalim | Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes |
| OTHER | Placebo | Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
- First posted
- 2023-06-05
- Last updated
- 2023-10-24
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05889442. Inclusion in this directory is not an endorsement.